3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
105
Neoplasm Metastasis
6
Neoplasms
4
Breast Diseases
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Hereditary Sensory and Autonomic Neuropathies
3
Carcinoma, Ovarian Epithelial
3
Breast Neoplasms, Male
3
Triple Negative Breast Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Endometrial Neoplasms
2
Breast Cancer Metastatic
2
Anatomic Stage II Breast Cancer AJCC v8
2
Advanced Breast Cancer
2
Venous Thromboembolism
1
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Osteitis Deformans
1
Neoplastic Cells, Circulating
1
Mesothelioma
1
Lymphoma
1
Lung Neoplasms
1
Locoregional Recurrence
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Leukemia
1
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
1
Hematologic Neoplasms
1
Interventions
pembrolizumab
19
Docetaxel
9
atezolizumab
8
Cetuximab
8
Nivolumab
7
cemiplimab
6
Ipilimumab
4
Immune Checkpoint Inhibitors
4
Gemcitabine
4
Drug Therapy
4
spartalizumab
3
palbociclib
3
fludarabine
3
durvalumab
3
avelumab
3
Trastuzumab
3
Radiotherapy
3
Paclitaxel
3
Oncolytic Virotherapy
3
Irinotecan
3
Fulvestrant
3
Fluorouracil
3
Cyclophosphamide
3
Carboplatin
3
Bortezomib
3
Blood Specimen Collection
3
seribantumab
2
selpercatinib
2
pazopanib
2
motexafin gadolinium
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
ribociclib
×
Breast
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled